Response: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes ( 2019; 34:382-9, Han Na Jang et al.).
作者信息
Jang Han Na, Jung Hye Seung
机构信息
Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
出版信息
Endocrinol Metab (Seoul). 2020 Mar;35(1):194-195. doi: 10.3803/EnM.2020.35.1.194.
Abstract
摘要
相似文献
1
Response: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes ( 2019; 34:382-9, Han Na Jang et al.).回应：2型糖尿病成人患者从基础胰岛素转换为每日一次德谷胰岛素/门冬胰岛素后血糖得到良好控制（2019年；34:382 - 389，Han Na Jang等人）
Endocrinol Metab (Seoul). 2020 Mar;35(1):194-195. doi: 10.3803/EnM.2020.35.1.194.
2
Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes ( 2019; 34:382-9, Han Na Jang et al.).信函：成人 2 型糖尿病患者从基础胰岛素转换为每日一次德谷胰岛素/门冬胰岛素后血糖控制良好（2019 年；34：382 - 389，Han Na Jang 等人）
Endocrinol Metab (Seoul). 2020 Mar;35(1):192-193. doi: 10.3803/EnM.2020.35.1.192.
3
Clinical use of the co-formulation of insulin degludec and insulin aspart.德谷胰岛素与门冬胰岛素复方制剂的临床应用
Int J Clin Pract. 2016 Aug;70(8):657-67. doi: 10.1111/ijcp.12821. Epub 2016 Jul 7.
4
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).一项比较利拉鲁肽与门冬胰岛素每日 1 次添加至德谷胰岛素在 2 型糖尿病患者中的疗效的研究（BEGIN：VICTOZA ADD-ON）。
Diabetes Obes Metab. 2014 Jul;16(7):636-44. doi: 10.1111/dom.12262. Epub 2014 Feb 11.
5
Premix insulins in type 1 diabetes: the coming of degludec/aspart.预混胰岛素在 1 型糖尿病中的应用：地特胰岛素/门冬胰岛素的问世。
Expert Opin Drug Metab Toxicol. 2019 Apr;15(4):341-348. doi: 10.1080/17425255.2019.1585427. Epub 2019 Mar 18.
6
Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus.在1型糖尿病患者中，德谷胰岛素在每日血糖变异性方面优于甘精胰岛素。
Endocr J. 2016;63(1):53-60. doi: 10.1507/endocrj.EJ15-0438. Epub 2015 Oct 31.
7
Insulin Degludec/Insulin Aspart: A Novel Co-formulation for Insulin Intensification.德谷胰岛素/门冬胰岛素：一种用于强化胰岛素治疗的新型复方制剂。
J Assoc Physicians India. 2015 May;63(5 Suppl):6-7.
8
A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.德谷胰岛素/门冬胰岛素综述：药代动力学和药效学特性及其在临床应用中的意义
Clin Pharmacokinet. 2017 Apr;56(4):339-354. doi: 10.1007/s40262-016-0455-7.
9
Comparison of effects of insulin aspart three times a day versus insulin detemir once a day on oxidative stress in patients with type 2 diabetes.每日三次门冬胰岛素与每日一次地特胰岛素对 2 型糖尿病患者氧化应激影响的比较。
Endocr J. 2011;58(12):1055-63. doi: 10.1507/endocrj.k11e-114. Epub 2011 Oct 8.
10
Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.德谷胰岛素，一种用于 1 型和 2 型糖尿病的长效每日一次基础胰岛素类似物。
Can J Diabetes. 2015 Feb;39(1):4-9. doi: 10.1016/j.jcjd.2014.02.019. Epub 2014 Jul 22.
本文引用的文献
1
Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes.在 2 型糖尿病成人中从基础胰岛素转换为每日一次德谷胰岛素/门冬胰岛素后的血糖良好控制。
Endocrinol Metab (Seoul). 2019 Dec;34(4):382-389. doi: 10.3803/EnM.2019.34.4.382.
2
9. Pharmacologic Approaches to Glycemic Treatment: .9. 血糖治疗的药物学方法： 。
Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110. doi: 10.2337/dc20-S009.
3
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.利西拉来（甘精胰岛素和利西那肽的可滴定固定比例复方制剂）对比甘精胰岛素和利西那肽单药治疗在口服药物控制不佳的 2 型糖尿病患者中的疗效：LixiLan-O 随机试验。
Diabetes Care. 2016 Nov;39(11):2026-2035. doi: 10.2337/dc16-0917. Epub 2016 Aug 15.
4
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond.胰高血糖素样肽-1受体激动剂的临床综述：在糖尿病及其他方面的疗效与安全性
Drugs Context. 2015 Jul 9;4:212283. doi: 10.7573/dic.212283. eCollection 2015.
Zotero 插件